NEWS
News and Updates from Usona
Usona in the News
Charles L. Raison: Elucidating the role of conscious experience in the therapeutic effects of psychedelics as a means to optimize clinical outcomes
Dr. Charles Raison talks with Genomic Press about his path from science enthusiast to leading psychedelic therapy researcher and its impacts.
March 14, 2024 | Genomic PressChasing Life with Dr. Sanjay Gupta: Treating the Depressed Brain featuring Dr. Charles Raison (Podcast)
As the use of antidepressants have steadily risen since their introduction in the 1980s, what have we learned about depression?
November 14, 2023 | CNNWhat Does Good Psychedelic Therapy Look Like?
As MDMA and psilocybin treatments become more mainstream, the therapy component has come under scrutiny. Here’s what’s common in many sessions...
June 3, 2023 | New York TimesWhen nothing else works
Could psychoactive substances like psilocybin, MDMA and ketamine finally crack the code on treatment-resistant depression, anxiety or PTSD?
May 2, 2023 | Madison MagazineKathleen Gallagher: How a Madison area non-profit is accelerating demand for psychedelic mushrooms used to treat mental illness
A look at the landscape of psychedelics being used to treat mental health and how Usona Institute to rising to meet the challenge.
August 9, 2022 | Milwaukee Journal SentinelAre you ready for the psychedelic revolution?
The psychedelic revolution in mental health treatment is on the way, with FDA approval likely in just a few years.
July 2, 2022 | NPR: To The Best of Our KnowledgeThese 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game.
June 2, 2022 | Business InsiderPsychedelic-assisted psychotherapy shakes off an old stigma
In the 1960s, the US limited research on psychedelics. Now, these once taboo substances are being recognized for their full medical potential.
March 16, 2022 | National Association of Science WritersUpdates
Usona Statement on Phase 3 Study of Psilocybin for Major Depressive Disorder (MDD) (uAspire)
March 20, 2024
Usona Institute Research Unveils New Compounds with Observed Psychedelic-like Activity
January 10, 2024
Usona statement on JAMA publication of PSIL201 data
August 31, 2023
Media Inquiries
MEDIA REQUESTMedia Inquiries
Please contact karen.burkhartzmeyer@usonainstitute.org with the following information:
- Name and organization
- Description of what you would like to cover
- Deadline